Company Profile

ICON GENETICS discovers and develops new biopharmaceuticals and high-value protein products using green plants as production hosts. We have developed new generation production platforms and product prototypes for pharmaceutical, animal health and chemical biotech markets. We offer new plant engineering technologies which address speed, yield, precision, expression control and safety of transgene management in plants.
ICON GENETICS AG, Munich, Germany has been incorporated in 1999. The Company owned two subsidiaries: ICON GENETICS GmbH, Halle, and ICON GENETICS Inc., NJ, USA. In January 2006, the Company has been acquired by BAYER INNOVATION GmbH, a wholly owned subsidiary of BAYER AG. In January 2007, ICON GENETICS AG has been merged into ICON GENETICS GmbH.
So far, ICON GENETICS has generated over 300 FTE-years of research, filed 39 patent applications and exclusively in-licensed 2 patents. Several patent applications are in preparation. ICON has published a number of milestone research papers in most important peer-review scientific journals.
As an independent company, we successfully raised capital in two investment rounds generating more than $12 million in equity and long-term debt.
Over 1999-2006 (prior to acquisition by BAYER), we raised more than $14 million in contracts, license fees and grants. Collaborations/contracts with Bayer Crop Science, Degussa, American Cyanamid, Schering, Large Scale Biology Corp., Meristem, Sunol, Fermentas, Novoplant, Institute of Plant Genetics and Crop Plant Research, Gatersleben, and Ludwig-Maximilians-University, Munich.
ICON GENETICS is managed by experienced directors and research managers with extensive knowledge of business and corporate research.